Skip to main content
P

PAIRE

PAIRE has developed Pionus, a Software as a Medical Device that utilizes AI to automatically detect, segment, and quantify anomalies in FDG PET-CT examinations. This technology enhances diagnostic accuracy and efficiency for nuclear physicians by reducing the time spent on repetitive tasks and providing new clinical indicators.

Paris, FranceFounded 202110700+ followers
Updated 8 months ago

Funding

$1.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

ALSMCPB

Founders

Product

Problem

Nuclear medicine faces increasing strain due to technical innovations, growing demand, and a limited number of physicians. This overload can impact diagnostic accuracy and efficiency in PET-CT examinations.

Solution

PAIRE addresses this challenge with Pionus, a Software as a Medical Device (SaMD) that leverages AI to automate the detection, segmentation, and quantification of anomalies in FDG PET-CT scans. Pionus enhances diagnostic accuracy by providing new clinical indicators and reduces the time spent on repetitive tasks. The AI-powered solution optimizes diagnostic processes, supporting the development of personalized precision medicine and improving patient care. By increasing diagnostic accuracy and reducing operational complexity, Pionus aims to steer nuclear medicine into a new era of greater efficiency and accessibility.

Target Audience

The primary users are nuclear physicians and healthcare systems seeking to optimize diagnostic processes, improve patient care, and alleviate the burden on the current healthcare system.

Features

  • AI-driven automatic detection, segmentation, and quantification of anomalies in FDG PET-CT examinations
  • Provides additional security to exam reading, preventing errors
  • Offers access to new essential indicators in clinical routine
  • Reduces redundant and time-consuming tasks, saving time for nuclear physicians
  • Supports the development of theranostic therapies and personalized precision medicine
  • CE marking under the European Medical Device Regulation (MDR 2017/745) and ISO 13485 certification
This profile is AI-generated and may contain inaccuracies.